Comparison · NCT01950234-344a9a45
ACTH vs Placebo: Safety and Tolerability of ACTH: Hair Loss
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ACTH vs Placebo: Safety and Tolerability of ACTH: Hair Loss. Trial comparisons, record NCT01950234-344a9a45. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01950234-344a9a45
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.241 | 0.122 | 0.421 | wilson | |
| Risk in group 2 | 0.233 | 0.118 | 0.409 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00805 | -0.204 | 0.222 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.414 | 2.58 | log | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.315 | 3.47 | log | |
| Number needed to treat, for one more participant with the outcome on ACTH than on Placebo | 124 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ACTH | ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month~ACTH: Acthar gel | 7 | 29 | OG000 |
| Group 2 | Placebo | Placebo subcutaneous injections administered on 3 consecutive days per month~Placebo: Placebo | 7 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Safety and Tolerability of ACTH: Hair Loss
- Description
- Count of participants self reporting at any time throuhgout the study that have noticed losing more hair
- Time frame
- Month 36
- Population
Source ClinicalTrials.gov
Trial
- Title
- ACTH in Progressive Forms of MS
- NCT number
- NCT01950234
- Phases
- PHASE2
- Conditions
- Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Interventions
- ACTH, Placebo
- Lead sponsor
- University of Minnesota
- Results first posted
- 2025-02-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01950234?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01950234-344a9a45